The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer

A. J. Armstrong, S. Halabi, R. de Wit, I. F. Tannock, Mario Eisenberger

Research output: Contribution to journalArticle

Abstract

The purpose of this study was to evaluate the relationship of baseline body mass index (BMI) and serum testosterone level with prostate cancer outcomes in men with castration-resistant metastatic prostate cancer (CRPC). BMI and testosterone levels were evaluated for their ability to predict overall survival (OS) and prostate-specific antigen (PSA) declines in the TAX327 clinical trial, an international phase III randomized trial of one of the two schedules of docetaxel and prednisone compared with mitoxantrone and prednisone. In this study of 1006 men with CRPC, the median serum testosterone level was 14.5ng per 100ml (range 0-270), the median BMI was 27kgm-2 (range 15.7-46.5), and 26% of men were obese or morbidly obese (BMI ≥ 30). Obesity was associated with younger age, lower PSA and alkaline phosphatase levels, and higher performance status, primary Gleason sum, testosterone and hemoglobin compared to absence of obesity. In multivariate analysis, neither BMI, presence of obesity, nor baseline testosterone was significantly associated with OS or PSA declines. Higher testosterone levels among obese men suggest incomplete gonadal suppression with current therapies, but these differences may not be clinically relevant in men with CRPC. There was evidence of potential hemodilution of PSA and alkaline phosphatase levels in obese men.

Original languageEnglish (US)
Pages (from-to)88-93
Number of pages6
JournalProstate Cancer and Prostatic Diseases
Volume12
Issue number1
DOIs
StatePublished - 2009

Fingerprint

Castration
Testosterone
Prostatic Neoplasms
Body Mass Index
Prostate-Specific Antigen
Serum
Obesity
docetaxel
Prednisone
Alkaline Phosphatase
Mitoxantrone
Phase III Clinical Trials
Hemodilution
Survival
Appointments and Schedules
Hemoglobins
Multivariate Analysis

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. / Armstrong, A. J.; Halabi, S.; de Wit, R.; Tannock, I. F.; Eisenberger, Mario.

In: Prostate Cancer and Prostatic Diseases, Vol. 12, No. 1, 2009, p. 88-93.

Research output: Contribution to journalArticle

@article{06146d31bef24640a76f3cd97bee36d6,
title = "The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer",
abstract = "The purpose of this study was to evaluate the relationship of baseline body mass index (BMI) and serum testosterone level with prostate cancer outcomes in men with castration-resistant metastatic prostate cancer (CRPC). BMI and testosterone levels were evaluated for their ability to predict overall survival (OS) and prostate-specific antigen (PSA) declines in the TAX327 clinical trial, an international phase III randomized trial of one of the two schedules of docetaxel and prednisone compared with mitoxantrone and prednisone. In this study of 1006 men with CRPC, the median serum testosterone level was 14.5ng per 100ml (range 0-270), the median BMI was 27kgm-2 (range 15.7-46.5), and 26{\%} of men were obese or morbidly obese (BMI ≥ 30). Obesity was associated with younger age, lower PSA and alkaline phosphatase levels, and higher performance status, primary Gleason sum, testosterone and hemoglobin compared to absence of obesity. In multivariate analysis, neither BMI, presence of obesity, nor baseline testosterone was significantly associated with OS or PSA declines. Higher testosterone levels among obese men suggest incomplete gonadal suppression with current therapies, but these differences may not be clinically relevant in men with CRPC. There was evidence of potential hemodilution of PSA and alkaline phosphatase levels in obese men.",
author = "Armstrong, {A. J.} and S. Halabi and {de Wit}, R. and Tannock, {I. F.} and Mario Eisenberger",
year = "2009",
doi = "10.1038/pcan.2008.36",
language = "English (US)",
volume = "12",
pages = "88--93",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer

AU - Armstrong, A. J.

AU - Halabi, S.

AU - de Wit, R.

AU - Tannock, I. F.

AU - Eisenberger, Mario

PY - 2009

Y1 - 2009

N2 - The purpose of this study was to evaluate the relationship of baseline body mass index (BMI) and serum testosterone level with prostate cancer outcomes in men with castration-resistant metastatic prostate cancer (CRPC). BMI and testosterone levels were evaluated for their ability to predict overall survival (OS) and prostate-specific antigen (PSA) declines in the TAX327 clinical trial, an international phase III randomized trial of one of the two schedules of docetaxel and prednisone compared with mitoxantrone and prednisone. In this study of 1006 men with CRPC, the median serum testosterone level was 14.5ng per 100ml (range 0-270), the median BMI was 27kgm-2 (range 15.7-46.5), and 26% of men were obese or morbidly obese (BMI ≥ 30). Obesity was associated with younger age, lower PSA and alkaline phosphatase levels, and higher performance status, primary Gleason sum, testosterone and hemoglobin compared to absence of obesity. In multivariate analysis, neither BMI, presence of obesity, nor baseline testosterone was significantly associated with OS or PSA declines. Higher testosterone levels among obese men suggest incomplete gonadal suppression with current therapies, but these differences may not be clinically relevant in men with CRPC. There was evidence of potential hemodilution of PSA and alkaline phosphatase levels in obese men.

AB - The purpose of this study was to evaluate the relationship of baseline body mass index (BMI) and serum testosterone level with prostate cancer outcomes in men with castration-resistant metastatic prostate cancer (CRPC). BMI and testosterone levels were evaluated for their ability to predict overall survival (OS) and prostate-specific antigen (PSA) declines in the TAX327 clinical trial, an international phase III randomized trial of one of the two schedules of docetaxel and prednisone compared with mitoxantrone and prednisone. In this study of 1006 men with CRPC, the median serum testosterone level was 14.5ng per 100ml (range 0-270), the median BMI was 27kgm-2 (range 15.7-46.5), and 26% of men were obese or morbidly obese (BMI ≥ 30). Obesity was associated with younger age, lower PSA and alkaline phosphatase levels, and higher performance status, primary Gleason sum, testosterone and hemoglobin compared to absence of obesity. In multivariate analysis, neither BMI, presence of obesity, nor baseline testosterone was significantly associated with OS or PSA declines. Higher testosterone levels among obese men suggest incomplete gonadal suppression with current therapies, but these differences may not be clinically relevant in men with CRPC. There was evidence of potential hemodilution of PSA and alkaline phosphatase levels in obese men.

UR - http://www.scopus.com/inward/record.url?scp=60349095199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60349095199&partnerID=8YFLogxK

U2 - 10.1038/pcan.2008.36

DO - 10.1038/pcan.2008.36

M3 - Article

C2 - 18574490

AN - SCOPUS:60349095199

VL - 12

SP - 88

EP - 93

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 1

ER -